Search Results - "Mather, Kieren"

Surrogate measures of insulin resistance: of rats, mice, and men by Mather, Kieren

Get more information

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity by Wharton, Sean, Blevins, Thomas, Connery, Lisa, Rosenstock, Julio, Raha, Sohini, Liu, Rong, Ma, Xiaosu, Mather, Kieren J., Haupt, Axel, Robins, Deborah, Pratt, Edward, Kazda, Christof, Konig, Manige

“…In this 36-week, randomized trial, daily oral orforglipron was associated with weight reduction, with efficacy and safety similar to those of injectable GLP-1…”
Get full text

Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study by Perreault, Leigh, MD, Pan, Qing, Mather, Kieren J, MD, Watson, Karol E, MD, Hamman, Richard F, MD DrPh, Kahn, Steven E, MB ChB

“…Summary Background Our objective was to quantify and predict diabetes risk reduction during the Diabetes Prevention Program Outcomes Study (DPPOS) in…”
Get full text

Cardiovascular consequences of metabolic syndrome by Tune, Johnathan D, Goodwill, Adam G, Sassoon, Daniel J, Mather, Kieren J

“…The metabolic syndrome (MetS) is defined as the concurrence of obesity-associated cardiovascular risk factors including abdominal obesity, impaired glucose…”
Get full text

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial by Heise, Tim, Mari, Andrea, DeVries, J Hans, Urva, Shweta, Li, Jing, Pratt, Edward John, Coskun, Tamer, Thomas, Melissa K, Mather, Kieren J, Haupt, Axel, Milicevic, Zvonko

“…Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, shows a remarkable ability to lower blood glucose, enabling many…”
Get full text

Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study by Frias, Juan P, Hsia, Stanley, Eyde, Sarah, Liu, Rong, Ma, Xiaosu, Konig, Manige, Kazda, Christof, Mather, Kieren J, Haupt, Axel, Pratt, Edward, Robins, Deborah

“…Orforglipron, an oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist, is in development for type 2 diabetes and obesity. We assessed the…”
Get full text

Effect of Prolonged Sitting and Breaks in Sitting Time on Endothelial Function by THOSAR, SAURABH S, BIELKO, SYLVANNA L, MATHER, KIEREN J, JOHNSTON, JEANNE D, WALLACE, JANET P

“…Sitting time (ST) is associated with cardiovascular disease risk factors, whereas breaking ST has been reported to be beneficial for reducing cardiovascular…”
Get full text

β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment by HALBAN, Philippe A, POLONSKY, Kenneth S, BOWDEN, Donald W, HAWKINS, Meredith A, LING, Charlotte, MATHER, Kieren J, POWERS, Alvin C, RHODES, Christopher J, SUSSEL, Lori, WEIR, Gordon C

“…This article examines the foundation of β-cell failure in type 2 diabetes (T2D) and suggests areas for future research on the underlying mechanisms that may…”
Get full text

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes by Heise, Tim, DeVries, J Hans, Urva, Shweta, Li, Jing, Pratt, Edward J, Thomas, Melissa K, Mather, Kieren J, Karanikas, Chrisanthi A, Dunn, Julia, Haupt, Axel, Milicevic, Zvonko, Coskun, Tamer

“…To evaluate the effects of tirzepatide on body composition, appetite, and energy intake to address the potential mechanisms involved in body weight loss with…”
Get full text

Effects of Resistance Training on Adiposity and Metabolism after Spinal Cord Injury by GORGEY, Ashraf S, MATHER, Kieren J, CUPP, Heather R, GATER, David R

“…This pilot work was conducted to evaluate the effects of neuromuscular electrical stimulation resistance training (RT) of the paralyzed knee extensor muscle…”
Get full text

Insulin resistance in the vasculature by Mather, Kieren J, Steinberg, Helmut O, Baron, Alain D

“…Insulin resistance is typically defined as a reduced ability of insulin to induce glucose uptake by target tissues such as fat and skeletal muscle cells. It…”
Get full text

The vascular endothelium in diabetes—a therapeutic target? by Mather, Kieren J.

“…Insulin resistance affects the vascular endothelium, and contributes to systemic insulin resistance by directly impairing the actions of insulin to…”
Get full text

Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium by Goldberg, Ronald B, Aroda, Vanita R, Bluemke, David A, Barrett-Connor, Elizabeth, Budoff, Matthew, Crandall, Jill P, Dabelea, Dana, Horton, Edward S, Mather, Kieren J, Orchard, Trevor J, Schade, David, Watson, Karol, Temprosa, Marinella

“…BACKGROUND:Despite the reduced incidence of coronary heart disease with intensive risk factor management, people with diabetes mellitus and prediabetes remain…”
Get full text

Prevalence of complications and co‐morbidities in males and females with obesity: Real‐world insights from claims data analysis by Bae, Jay P., Nelson, David R., Boye, Kristina S., Mather, Kieren J.

“…Aim To comprehensively examine the range of co‐morbidities among males and females with a diagnosis of obesity. Materials and Methods This cross‐sectional…”
Get full text

Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist by Benichou, Olivier, Coskun, Tamer, Gonciarz, Malgorzata D., Garhyan, Parag, Adams, Andrew C., Du, Yu, Dunbar, James D., Martin, Jennifer A., Mather, Kieren J., Pickard, Richard T., Reynolds, Vincent L., Robins, Deborah A., Zvada, Simbarashe P., Emmerson, Paul J.

“…GDF15 and its receptor GFRAL/RET form a non-homeostatic system that regulates food intake and body weight in preclinical species. Here, we describe a GDF15…”
Get full text

56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting by KNOP, FILIP K., URVA, SHWETA, RETTIGANTI, MALLIKARJUNA, BENSON, CHARLES, ROELL, WILLIAM, MATHER, KIEREN J., HAUPT, AXEL, PRATT, EDWARD J.

“…The contributions of glucose-dependent insulinotropic polypeptide (GIP) to overall metabolic and weight effects of incretin therapies are unclear. Weight loss…”
Get full text

Effects of Tirzepatide vs Semaglutide on β-cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test by Mather, Kieren J, Mari, Andrea, Heise, Tim, DeVries, J Hans, Hua, Ming, Urva, Shweta, Coskun, Tamer, Haupt, Axel, Heine, Robert J, Pratt, Edward, Thomas, Melissa K, Milicevic, Zvonko

“…In a clinical study, tirzepatide, a glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist (GIP/GLP-1RA), provided superior…”
Get full text

β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment by Halban, Philippe A, Polonsky, Kenneth S, Bowden, Donald W, Hawkins, Meredith A, Ling, Charlotte, Mather, Kieren J, Powers, Alvin C, Rhodes, Christopher J, Sussel, Lori, Weir, Gordon C

“…OBJECTIVE: This article examines the foundation of β-cell failure in type 2 diabetes (T2D) and suggests areas for future research on the underlying mechanisms…”
Get full text

Improvements in post‐challenge lipid response following tirzepatide treatment in patients with type 2 diabetes by Mather, Kieren J., Coskun, Tamer, Pratt, Edward J., Milicevic, Zvonko, Weerakkody, Govinda, Thomas, Melissa K., Haupt, Axel, Ruotolo, Giacomo

Get full text

229-OR: Orforglipron Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes by ROSENSTOCK, JULIO, ROBINS, DEBORAH A., DUFFIN, KEVIN L., WILSON, JONATHAN M., MATHER, KIEREN J., BANERJEE, HIYA, LIN, YANZHU, EYDE, SARAH, KAZDA, CHRISTOF M., KONIG, MANIGE

“…Orforglipron (OFG), an oral, non-peptide GLP-1 receptor agonist, demonstrated significantly greater glycemic control and weight loss at doses ≥12 mg vs placebo…”
Get full text